A highly expressed miR-101 isomiR is a functional silencing small RNA by Llorens Torres, Franc et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
A highly expressed miR-101 isomiR is a functional silencing small RNA
BMC Genomics 2013, 14:104 doi:10.1186/1471-2164-14-104
Franc Llorens (franc.llorens@gmail.com)
Mónica Bañez-Coronel (monica.banez@crg.eu)
Lorena Pantano (lorena.pantano@gmail.com)
Jose Antonio del Río (jadelrio@ibecbarcelona.eu)
Isidre Ferrer (8082ifa@gmail.com)
Xavier Estivill (xavier.estivill@crg.cat)
Eulàlia Martí (eulalia.marti@crg.cat)
ISSN 1471-2164
Article type Research article
Submission date 15 August 2012
Acceptance date 30 January 2013
Publication date 15 February 2013
Article URL http://www.biomedcentral.com/1471-2164/14/104
Like all articles in BMC journals, this peer-reviewed article can be downloaded, printed and
distributed freely for any purposes (see copyright notice below).
Articles in BMC journals are listed in PubMed and archived at PubMed Central.
For information about publishing your research in BMC journals or any BioMed Central journal, go to
http://www.biomedcentral.com/info/authors/
BMC Genomics
© 2013 Llorens et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A highly expressed miR-101 isomiR is a functional 
silencing small RNA 
Franc Llorens1,2,3 
Email: franc.llorens@gmail.com 
Mónica Bañez-Coronel4,5,6 
Email: monica.banez@crg.eu 
Lorena Pantano7 
Email: lorena.pantano@gmail.com 
Jose Antonio del Río1,2,3 
Email: jadelrio@ibecbarcelona.eu 
Isidre Ferrer3,8 
Email: 8082ifa@gmail.com 
Xavier Estivill4,5,6,* 
Email: xavier.estivill@crg.cat 
Eulàlia Martí4,5,6,* 
Email: eulalia.marti@crg.cat 
1
 Molecular and Cellular Neurobiotechnology Group, Institut de Bioenginyeria de 
Catalunya (IBEC), Parc Científic de Barcelona, Barcelona, Spain 
2
 Department of Cell Biology, University of Barcelona (UB), Barcelona, Spain 
3
 Network Biomedical Research Center for Neurodegenerative Diseases 
(CIBERNED), Barcelona, Spain 
4
 Genetic Causes of Disease Group, Genes and Disease Program, Centre for 
Genomic Regulation (CRG) and UPF, Barcelona, Spain 
5
 Universitat Pompeu Fabra (UPF), Barcelona, Spain 
6
 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, 
(CIBERESP), Barcelona, Spain 
7
 Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona, Spain 
8
 Institut Neuropatologia, Servei Anatomia Patològica, IDIBELL-Hospital 
Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain 
*
 Corresponding author. Centro de Investigación Biomédica en Red de 
Epidemiología y Salud Pública, (CIBERESP), Barcelona, Spain 
Abstract 
Background 
MicroRNAs (miRNAs) are short non-coding regulatory RNAs that control gene expression 
usually producing translational repression and gene silencing. High-throughput sequencing 
technologies have revealed heterogeneity at length and sequence level for the majority of 
mature miRNAs (IsomiRs). Most isomiRs can be explained by variability in either Dicer1 or 
Drosha cleavage during miRNA biogenesis at 5’ or 3’ of the miRNA (trimming variants). 
Although isomiRs have been described in different tissues and organisms, their functional 
validation as modulators of gene expression remains elusive. Here we have characterized the 
expression and function of a highly abundant miR-101 5’-trimming variant (5’-isomiR-101). 
Results 
The analysis of small RNA sequencing data in several human tissues and cell lines indicates 
that 5’-isomiR-101 is ubiquitously detected and a highly abundant, especially in the brain. 5’-
isomiR-101 was found in Ago-2 immunocomplexes and complementary approaches showed 
that 5’-isomiR-101 interacted with different members of the silencing (RISC) complex. In 
addition, 5’-isomiR-101 decreased the expression of five validated miR-101 targets, 
suggesting that it is a functional variant. Both the binding to RISC members and the degree of 
silencing were less efficient for 5’-isomiR-101 compared with miR-101. For some targets, 
both miR-101 and 5’-isomiR-101 significantly decreased protein expression with no changes 
in the respective mRNA levels. Although a high number of overlapping predicted targets 
suggest similar targeted biological pathways, a correlation analysis of the expression profiles 
of miR-101 variants and predicted mRNA targets in human brains at different ages, suggest 
specific functions for miR-101- and 5’-isomiR-101. 
Conclusions 
These results suggest that isomiRs are functional variants and further indicate that for a given 
miRNA, the different isomiRs may contribute to the overall effect as quantitative and 
qualitative fine-tuners of gene expression. 
Keywords 
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Background 
miRNAs are small non-coding RNAs that generally act as negative post-transcriptional 
regulators of gene expression. It is estimated that miRNAs regulate at least 20% of human 
genes [1], constituting an important layer of regulation in gene expression networks. The 
influence of a particular miRNA on the transcriptome is difficult to dissect, since genes can 
harbor binding sites for several miRNAs, and a specific miRNA can modulate the expression 
of hundreds of mRNA targets [2]. miRNAs are involved in almost every biological process 
examined and their deregulation has been associated with a number of pathological 
conditions, including cancer and neurological disorders [3-6]. 
Mature miRNAs function as components of the RNA-Induced Silencing Complex (RISC) 
[7], guiding the RISC to specific gene targets through base-pairing interactions between the 
miRNA and the mRNA. Members of the Argonaute (Ago) protein family are central to RISC 
function. The seed region extends from the second to the seventh or eighth position of mature 
miRNA and has traditionally been considered as a major determinant of the target mRNA 
repertoire, through perfect base pairing with the 3’-untranslated regions (3’-UTR) of mRNAs 
[8]. Other structures of the 3’-end of the miRNA are also involved in duplex stability, 
providing a supplementary site if the seed is fully paired or a compensatory site when the 5’-
end has mismatches or bugles [9,10]. However, our knowledge of the determinants governing 
gene targeting is far from complete. In fact, recent findings show that targeting can occur 
through sites other than the 3’-UTR, and that seed region perfect base pairing is not always 
required [11-14]. This miRNA/mRNA binding leads either to target mRNA degradation or to 
translational inhibition, depending, among other factors, on the extent of base-pairing and the 
type of RISC/Ago proteins [15]. 
A novel degree of complexity for miRNA transcriptome has been highlighted using next 
generation sequencing (NGS) strategies. NGS has revealed post-transcriptional editing 
processes in miRNAs, mainly consisting in variations in the 3’- and 5’-terminus and to a 
minor extent, nucleotide substitutions along the miRNA sequence [16-19]. Variations at the 
miRNA ends may be generated by a shift in Drosha and Dicer cleavage sites during miRNA 
biogenesis (trimming variants) [19,20]. Another type of variability is related to pri-miRNA 
post-transcriptional editing as a consequence of adenosine or cytidine deaminase activity 
(nucleotide substitution variants). Finally, nucleotide additions at the 3’-end of the miRNA 
are another source of miRNA variability [21-23]. The resulting sequences differ slightly from 
the annotated miRNA and have been termed isomiRs [19]. 
Several lines of evidence suggest that isomiRs are not experimental artifacts derived from 
RNA degradation during sample preparation for NGS [24,25]. In fact the frequencies of 
nucleotide substitutions are very diferent from sequencing error rates; and the detection of 
isomiRs in many species, tissues and physiological conditions [26,27], suggests that they may 
have a biological role. This notion is further supported by their differential expression across 
developmental stages [27,28]. This scenario suggests that, for a given miRNA, 
posttranscriptional gene expression may depend on different isomiRs. However, their 
functionality as posttranscriptional gene expression regulators needs to be proven. Our recent 
studies of miRNA profiling in human brain samples have shown a multitude of miRNA 
variants [16]. miR-101 is an interesting example, since it presents 5’-trimming isomiRs (5’-
isomiR-101) expressed at levels similar to those of the reference sequence. Here, we 
characterize the ability of this highly expressed human isomiR-101 to work as a functional 
miRNA. 
Results 
miR-101 and miR-101 5’-isomiRs are expressed at different proportions in 
different human samples 
We have shown that the vast majority of miRNAs in human frontal cortex and striatum 
display sequence variants or isomiRs [16]. Several factors may modulate the physiological 
relevance of an isomiR, including i) the amount of the isomiR in relation to the rest of 
sequences mapping onto the same miRNA locus and ii) the type of variant, with special 
emphasis on nucleotide changes affecting the seed region. Sequencing data analysis of these 
brain areas showed that miR-101 was an abundant miRNA, represented by approximately 
100 unique isomiRs (> 10 counts per sequence), although deeper sequencing performed in 
other brain samples identified more variants (Figure 1, Additional file 1 Table S1). The 
different miR-101 isomiRs consisted in trimming variants, nucleotide additions at the 3’ end 
of the miRNA and nucleotide substitutions at different positions along the mature miRNA 
(Figure 1, Additional file 1 Table S1, Figure 2A). The distribution of the different types of 
miR-101 isomiRs was confirmed in the prefrontal cortex of human brains at different ages in 
an independent sequencing experiment [26] (Figure 2A). Trimming variants affecting the 5’ 
end of the miRNA (5’-isomiRs) were among the more abundant species. In fact, the vast 
majority of miR-101 5’-isomiRs affected a single nucleotide upstream of the reference miR-
101, therefore defining a new seed region. Thus, taking into consideration all the sequences 
mapping onto miR-101, two main types of seeds were found: ACAGUAC, which is reported 
in the miRBase, and UACAGUA, corresponding to the vast majority of miR-101 5’-isomiRs. 
We examined the presence of miR-101 5’-isomiRs in another brain area (amygdala) from 
four individuals without major histopathological lesions and no clinical neuropathology and 
in peripheral blood from four healthy individuals, and further analyzed several public high-
throughput sequencing datasets from the GEO repository corresponding to human brains at 
different developmental stages [26] and different human cell lines [29] (Figure 2B). This 
analysis indicated that miR-101 5’-isomiRs are expressed at high proportions in different 
human cells, thus suggesting a physiological role for these variants. Furthermore, the 
proportion of each of the major seed regions differs according to the cell type, which suggests 
a differential modulation of the biogenesis and/or stability of the different miR-101 variants. 
Figure 1 miR-101 variants in the human frontal cortex. The different sequences 
annotating to miR-101, the respective frequencies and lengths are shown. For the 5’ and 3’ 
trimming variants, the number of nucleotides upstream (up) or downstream (down) of the 
reference miRBase miR-101 (highlighted in blue), are shown. The nucleotides involved in the 
5’- and 3’ variant are next indicated. In 3’-addition variants, the number and type of 
nucleotides added to the 3’-ends are shown. In the nucleotide substitution variants, the 
affected position is first indicated; the pair of nucleotides that follow next indicates the 
substituted and the original nucleotides, respectively. Only variants with more than 10 counts 
are shown. The more abundant sequences mapping onto miR-101 locus that represent the 
reference miR-101 sequence (in blue) and the 5’-isomiR-101 (in red) contained in a grey box 
are the chosen sequences for functional assays in transfection. 
Figure 2 miR-101 and 5’-isomiR-101 are abundant in different cells and tissues. A. 
Relative frequencies of miR-101 isomiRs in human brain samples. The percentage of 5’- and 
3’-trimming isomiRs, 3’ nucleotide additions and nucleotide substitutions was determined in 
sRNA sequencing data sets of the frontal cortex (FC) and striatum (ST) of a control 
individual [16] and prefrontal cortex (pFC, 98 years old and pFC, 2 days old) [26]. The 
summed frequency of the total of sequences mapping onto miR-101 was considered as the 
100 %. B. Percentage of each of the two main seed regions in human brain (4 individuals) 
and blood (4 individuals), and several human cell lines [29]. A scheme is included showing 
miR-101 precursor and mature forms. The mature miR-101 is highlighted in red. The arrows 
point to the major cleavage sites giving rise to the most abundant mature miR-101 variants. 
The seed regions in each variant are contained in a blue box. C. Abundance of miR-101 in 
human blood and brain samples and in cell lines. These corresponded to amygdala (am) of 4 
individuals frontal cortex (fc) of two individuals aging 25 and 66 years [26] and different 
types of cells [29]. In each sample, the percentage of sequences mapping onto miR-101 is 
calculated with respect to the total of sequences mapping onto miRNA database. D. miR-101 
and 5’-isomiR-101 expression in the frontal cortex and the striatum of control individuals (C) 
and patients with HD [16]. E. miR-101 and 5’-isomiR-101 expression in undifferentiated and 
differentiated SH-SY5Y cells. F. miR-101 and 5’-isomiR-101 expression in the frontal cortex 
of individuals at different ages [26]. In D, E, F normalized counts are expressed as the ratio: 
(frequency of sequences presenting miR-101 or 5’isomiR-101 seed regions) / (frequency of 
sequences mapping onto miRNAs) * 10E6. When more than a biological replica is available 
(B and C) data are presented as the mean ± standard deviation. SH: SH-SY5Y human 
neuroblastoma cell line, Fibro: Fibrocytes, HEK: human embryonic kidney 293 cells, 143B: 
human bone osteosarcoma 143B cell line, H520: human squamous cell carcinoma H520 cell 
line, MCF7: human breast cancer MCF7 cell line, U2S: human osteosarcoma U2S cell line, 
HeLa: human cervical cancer HeLa cell line. 
Considering all the sequencing datasets examined, the percentage of sequences mapping onto 
miR-101 varied between tissues and cell lines, with the brain presenting the highest levels 
(Figure 2C). These data suggest that high miR-101 levels may be important for adult brain 
physiology. In fact, miR-101 expression is regulated under a number of physiological and 
pathological conditions, including angiogenesis [30], tumors [31,32] and neurodegeneration 
[16,33,34]. In the last condition, our earlier study identified miR-101 as an up-regulated gene 
in HD [16]. However, that study was an overall analysis of all the sequences mapping onto 
miR-101. To discern the specific expression pattern of miR-101 5’-isomiRs, we evaluated the 
expression of miR-101 variants harboring each of the two main seeds in control brains and 
brains of patients with HD (Figure 2D). Both types of variants were up-regulated in the 
frontal cortex and striatum of HD patients. In addition, we performed a similar analysis in 
other physiological conditions of the nervous system, including in vitro differentiation of the 
SH-SY5Y neuronal cell line to a postmitotic dopaminergic phenotype (Figure 2E) and early 
postnatal development and ageing of the human brain [26] (Figure 2F). Interestingly, the 
relative amounts of both types of miR-101 variants in the brain differed according to age. 
These data suggest that miR-101 is modulated in the development and differentiation 
processes of the nervous system. Furthermore, the context-dependent variations in the 
relative amounts of miR-101 and 5’-isomiR-101 suggest that the mechanisms regulating their 
biogenesis and/or stability may differ depending on the biological process. 
miR-101 and 5’-isomiR-101 interact with Ago2 and Rck/p54 
Functional studies aiming to elucidate the possible relevance of the more abundant miR-101 
isomiRs in the nervous system were performed in the neuronal cell line SH-SY5Y. We used 
miRNA mimics for two abundant representative sequences containing ACAGUAC or 
UACAGUA seeds: The miRBase reference miR-101 UACAGUACUGUGAUAACUGAA, 
and one of the most abundant miR-101 5’-isomiRs presenting the same length as the 
reference miR-101 GUACAGUACUGUGAUAACUGA (Figure 1). 
We used highly specific LNA™ RT-qPCR assay (Exiqon™) for selective detection of miR-
101 or 5’-isomiR-101. To test the specificity of the detection, we transfected equivalent 
amounts of either miR-101 or 5’-isomiR-101 mature mIRIDIAN-mimics or a control 
sequence into SH-SY5Y cells and determined the amount of miR-101 and 5’-isomiR-101 
using the corresponding assays (Figure 3A). Fold changes are expressed relative to the cells 
transfected with the control sequence. The miR-101 RT-qPCR specific assay clearly detected 
miR-101 while 5’-isomiR-101 was very weakly amplified (Figure 3A, left bars). A 
complementary result was obtained using the 5’-isomiR-101 RT-qPCR specific assay (Figure 
3A, right bars), indicating that both assays are highly selective for each variant. 
Figure 3 miR-101 and 5’-isomiR-101 bind Ago2 and Rck/p54. A. Specificity of miR-101 
and 5’-isomiR-101 detection. SH-SY5Y cells were transfected with a negative control 
sequence (siGLO Green) or the mIRIDIAN mimics for miR-101 (dark bars) or 5’-isomiR-
101 (light bars). Specific RT-qPCRs determinations for miR-101 and 5’-isomiR-101 were 
performed. Results are expressed as the Fold Change ratios (miridian mimic / control 
siGLO). B. Expression of exogenously transfected miR-101 or 5’-isomiR-101 in Ago2 
immunocomplexes. SH-SY5Y cells were transfected with Siglo Green or the mIRIDIAN 
mimics for miR-101 or 5’-isomiR-101. Specific RT-qPCRs were performed in Ago2-FLAG 
immunoprecipitates.Results are expressed as the Fold Change ratios obtained from the FLAG 
antibody/Control antibody immunoprecipitates. Western-blot with anti-FLAG antibody 
shows the presence of Ago2-FLAG in the FLAG-IP and input, and the absence of Ago2-
FLAG in the control IP. C. Detection of RISC components in miR-101 or 5’-isomiR-101 
pull-down. SH-SY5Y cells stably expressing Ago2-FLAG were transfected with mIRIDIAN 
3’-biotin-miR-101 or 3’-biotin-5’-isomiR-101. Biotin-miRNA complexes were pulled down 
with streptavidin beads and subsequently assayed for western blot analysis using Ago2 and 
Rck/p54 antibodies. The relative amount of Ago2 and Rck/p54 in 3’-biotin-5’-isomiR-101 
versus 3’-biotin-miR-101 is shown in the middle panel. miRNA-101 transfected samples 
were used to normalize data and were assigned a value of 1. Left panel shows similar 
amounts of transfected 3’-biotin-miR-101 or 3’-biotin-5’-isomiR-101 determined in total cell 
extracts with the corresponding specific RT-qPCR assays. D. Expression of endogenous miR-
101 and 5’isomiR-101 in Ago2-immunocomplexes in the human brain. Ago2 complexes 
were immunoprecipitated from human frontal cortex homogenates and miR-101, 5’-isomiR-
101, miR-29a, U6 SNORD44 were determined by RT-qPCR. Results are expressed as the 
Fold Change ratios obtained from the Ago2 vs denatured Ago2 immunoprecipitates. Three 
independent experiments were performed in A-D. All data are expressed as the mean± SEM. 
Asterisks indicate statistical significance between miR-101 and 5’-isomiR-101 data : * (p ≤ 
0.05), ** (p≤0.01) using Mann–Whitney test. 
We then examined whether transfected miR-101 and 5’-isomiR-101 mIRIDIAN were 
incorporated into the RISC, using SH-SY5Y cells stably expressing Ago2-FLAG. We 
performed immunoprecipitation (IP) assays using anti-FLAG antibodies for Ago2-IP or 
control antibodies, and subsequently RNA in the IP was isolated. We detected a significant 
enrichment of either miR-101 or 5’-isomiR-101 in Ago2 IP. The amount of miR-101 or 5’-
isomiR-101 in cells transfected with the corresponding miRNA mimics was similar (Figure 
2A). However, increased amounts of miR-101 were detected in the Ago2 IP, compared with 
5’-isomiR-101 (Figure 3B), suggesting that miR-101 was more efficiently loaded into RISC. 
The ability of miR-101 and 5’-isomiR-101 to bind to the RISC was further confirmed in 
complementary experiments designed to evaluate the presence of RISC members in 
transfected biotinylated miR-101 and 5’-isomiR-101 (Figure 3C). mIRIDIAN 3’-biotin-miR-
101 and 3’-biotin-5’-isomiR-101 were transfected in SH-SY5Y cells and then pulled down 
using streptavidin beads. The samples were blotted against Ago2 and Rck/p54 which 
represses translation and associates with the RISC complex in order to regulate miRNA 
mediated gene silencing [35]. Both biotin-miR-101 and biotin-5’-isomiR-101 were able to 
interact with Ago2 and Rck/p54. Although similar levels of each biotinylated mIRIDIAN 
were detected in transfected SH-SY5Y cells, increased levels of both proteins were found in 
biotin-miR-101 pull downs compared with those of biotin-5’-isomiR-101. This result 
suggests that miR-101 binds with RISC members more efficiently, which is in agreement 
with results shown in Figure 2B. 
To validate the presence of both variants in endogenous RISC, we immunoprecipitated Ago2 
from the human frontal cortex. The control experiment included a sample in which the Ago2 
antibody had previously been denaturized (d-Ago2) and was therefore unable to interact with 
Ago2. Total RNA was isolated from Ago2 and d-Ago2 IPs and subsequently we performed 
RT-qPCR for miR-101, 5’-isomiR-101, miR-29a, SNORD44 and U6. Data were expressed as 
the fold change obtained from the Ago2 vs d-Ago2 crossing thresholds (CTs) (Figure 3D). 
miR-101 and 5’-isomiR-101 were enriched in Ago2 IPs compared to control d-Ago2 
antibody. miR-29a, a highly abundant miRNA in brain [16] was also enriched in Ago2 
complexes. In contrast, the small nucleolar RNAs U6 and SNORD44, which were not 
expected to bind Ago2, were detected at insignificant levels. The presence of both types of 
miR-101 variants in Ago2 immunocomplexes was confirmed in publicly available high-
throughput sequencing data of endogenous Ago2-associated sRNAs in HEK293T and mouse 
NIH-3T3 cells (GEO datasets GSM337571 and GSM849857 respectively). 
To evaluate the possibility that 5’-isomiR-101 and miR-101 are sorted into different Agos, 
we analyzed publicly available small-RNA sequencing datasets from Ago1, Ago2 and Ago3 
IP and total cell extracts, in THP-1 human monocytic cells [36] (Additional file 2 Figure S1). 
We found all types of miR-101 in each Ago (the trimming, substitution and 3’-additions 
variants). In addition, the percentage of miR-101 sequences loaded onto each Ago was 
comparable. Grouping the variants according to the two main seeds we found that in total cell 
homogenates the ratio miR-101/5’-isomiR-101 in THP-1 cells was close to 2. However, this 
ratio varied slightly depending on the Ago protein, with the highest levels being found in 
Ago2 and the lowest in Ago3. This suggests that although in terms of quantity miR-101 
exceeded 5’-IsomiR-101 in all Agos, miR-101 species loaded more onto Ago2 than 5’-
isomiR-101 variants. This is in agreement with our findings for SH-SY5Y. 
miR-101 and 5’-isomiR-101 differentially repress COX-2, Mcl-1, APP, EZH2 
and MKP-1 expression 
Since miR-101 and 5’-isomiR-101 have a different seed region, we evaluated the predicted 
conserved targets for each variant, using the TargetScan 5.2 release [37], by searching for the 
presence of 8mer and 7mer sites that match miR-101 and 5’-isomiR-101 seed regions. 
TargetScan 5.2 detected that the majority of putative mRNA targets (>70%) were 
coincidental, suggesting that miR-101 and 5’-isomiR-101 may target highly overlapping 
pathways. In an attempt to identify possible differentially deregulated genes, SH-SY5Y cells 
were transfected with miR-101 or 5’-isomiR-101 mimics or a scrambled mimic in three 
independent experiments, and 48 h later overall gene expression was evaluated using 
Illumina microarrays (HumanHT Expression BeadChips). Transfection of each miR-101 
variant resulted in few significantly deregulated genes that showed few changes in expression 
(q<5 %, fold change < −1,2 or > 1,2; Additional file 3 Table S2–Additional file 4 Table S3). 
miR-101 induced a significant downregulation of 16 genes, eight being targeted by at least 
one prediction algorithm. Nine out of the 16 genes were also downregulated by 5’-isomiR-
101 (q<10 %), while the rest did not show significant variations. Thus, 5’-isomiR-101 seems 
to induce an overall weaker inhibition. In agreement, transfection of 5’-isomiR-101 resulted 
in a slight downregulation of two genes, for which miR-101 did not induce significant 
expression changes. These data indicate that under our experimental conditions modulation of 
gene expression by miR-101 or 5’-isomiR-101 may not involve mRNA degradation as the 
main mechanism, and suggest further that miR-101 inhibits gene expression more efficiently 
than 5’-isomiR-101. 
To gain insights into the possible role of 5’isomiR-101 in physiological conditions, we 
analyzed publicly available mRNA and small-RNA datasets of human brain samples at 
multiple time-points between early postnatal development and aging [38]. We chose this 
paradigm for two reasons: i/ miR-101 expression levels increased through aging, suggesting a 
role in this process (Figure 2F), and ii/ variants carrying each seed are not equally expressed 
at the different time-points (compare the oldest and the middle-aged individuals, Figure 2F), 
suggesting a seed-specific role in the modulation of the age-related genes. 
To assess the possible seed-specificity in the modulation of the age-related transcriptome, we 
analyzed the correlation between the expression of miR-101 variants and that of the age-
related genes at different ages through life. First, we generated a list of candidate age-related 
genes through a multiple regression analysis of the gene expression profiles using age as the 
predicted variable (a total of 3801). We then identified the miR-101 or 5'-isomiR-101 
predicted targets among the pool of age-related genes, using the TargetScan 5.2 algorithm 
(837 for miR-101 and 899 for 5’-isomiR-101, out of the 3801; the majority, 73%-78%, were 
common to the two miR-101 seeds). Finally, we measured the correlation between the 
expression levels of age-related genes and those of the most abundant reference seed 
sequence (miR-101, UACAGUACUGUGAUAACUGAA) or the most abundant 5’-isomiR 
sequence (5’-isomiR-101, GUACAGUACUGUGAUAACUGA). 
The negative correlation between the expression profiles of the mRNAs and those of miR-
101 or 5’-isomiR-101 was considered the readout for miR-101 or 5’-isomiR-101 
effective/detectable gene targeting. The expression of a total of 64 and 153 age-related genes 
anti-correlated with that of the ref-miR-101 or 5’-isomiR-101 respectively (r<−0.7), with a 
significantly lower number of common genes between the two miR-101 seeds (16%-39%, 
p<0.01). These results indicate that the majority of anti-correlated targets were seed-specific, 
which supports the notion of a selective function of each miR-101 variant in modulating age-
related genes (Additional file 5 Figure S2). 
Several targets have been validated for miR-101, including the cyclooxygenase 2 (COX-2) 
[39], the myeloid leukemia cell differentiation protein (MCL-1) [38], the amyloid precursor 
protein (APP) [40], the enhancer of zeste homolog 2 (EZH2) [41] and the MAP kinase 
phosphatase 1 (DUSP1/MKP-1) [42]. Of these, DUSP1/MKP-1, APP and EZH2 mRNAs 
were predicted as possible targets of both miR-101 and 5’-isomiR-101. Transfection of SH-
SY5Y cells with either miR-101 or 5’-isomiR-101 mimics slightly decreased mRNA levels of 
COX-2, MCL-1, APP and DUSP1 (MKP-1) compared with cells transfected with a 
scrambled-control sequence, although the differences observed were not statistically 
significant (Figure 4A). In contrast, miR-101 expression significantly decreased EZH2 
mRNA levels, by 40%. A tendency for EZH2 down-regulation by miR-101 was also detected 
in the microarrays (fold change = −1.2; q = 15%). These findings corroborate previous results 
showing that miR-101 repressed the expression of certain genes at the protein level [38-
40,42], while only EZH2 mRNA showed decay [41]. Our data indicate that, although similar 
amounts of miR-101 and 5’-isomiR-101 were delivered into neuronal cells, 5’-isomiR-101 
inhibited EZH2 mRNA expression by 20%, suggesting that this variant is functional. 
Figure 4 miR-101 and 5’-isomiR-101 differentially regulate gene expression. A. mRNA 
expression of miR-101 target genes following exogenous expression of miR-101 or 
5’isomiR-101. After transfection of SH-SY5Y cells with the siGLO control sequence (Con) 
or the mIRIDIAN mimics for miR-101 or 5’-isomiR-101 the expression of COX-2, MCL-1, 
APP, EZH2 and DUSP-1 (MKP-1) was determined by RT-qPCRs. A control sample was 
used to normalize Fold Change values in each set of experiments. This control sample was 
assigned a value of 1. B. Protein expression of miR-101 target genes following exogenous 
expression of miR-101 or 5’isomiR-101. Western blot determination of COX-2, MCL-1, 
APP, EZH2 and DUSP-1 (MKP-1) levels in SH-SY5Y were performed in cells transfected 
with a control sequence (Con) and the mIRIDIAN mimics for miR-101 or 5’-isomiR-101. A 
control sample was used to normalize Fold Change values in each set of experiments. This 
control sample was assigned a value of 1. C. Expression of miR-101 target genes cells 
transfected with miR-101 and 5’-isomiR-101 biotynilated isomiRs. SH-SY5Y cells were 
transfected with Biotin, mIRIDIAN 3’-biotin-miR-101 or 3’-biotin-5’-isomiR-101. Biotin-
miRNA complexes were pulled down with streptavidin beads and the expression of COX-2, 
MCL-1, APP, EZH2 and DUSP-1 (MKP-1) mRNA was determined by RT-qPCRs. Results 
are expressed as the Fold Change ratios obtained from the biotin-tagged miR-101 and 5’-
isomiR-101 transfected cells versus the biotin transfected control cells. ND: Not detectable. 
All data are expressed as the mean ± SEM from at least three independent experiments. 
Asterisks indicate statistical significance between miR-101 and 5’isomiR-101 data: ** 
(p≤0.01), * (p≤0.5) using the Mann–Whitney test. 
To further confirm 5’-isomiR-101 functionality we determined the effect of miR-101 and 5’-
isomiR-101 mimics on the expression of COX-2, MCL-1, APP, EZH2 and MKP-1 at the 
protein level (Figure 4B). We found that comparable expression levels of exogenously 
transfected miR-101 or 5’-isomiR-101 in SH-SY5Y cells decreased the expression of all 
proteins. However, miR-101 produced a significantly higher down-regulation of the proteins 
studied compared with 5’-isomiR-101 (Figure 4B). In SH-SY5Y cells, miR-101 repressed the 
expression of COX-2, MCL-1, EZH2, APP and MKP-1 at the same levels as those reported 
in other cell systems [38-42]. 
The decreased silencing activity of 5’-isomiR-101 agrees with the reduced binding of this 
variant to Ago2 complexes. To further confirm that the target mRNAs were less represented 
in the RISC, we transfected SH-SY5Y cells with 3’biotinylated miR-101 and 5’-isomiR-101 
mimics and subsequently pulled down the complexes with streptavidin. Both 3’biotinylated-
miR-101 and 3’biotinylated-5’-isomiR-101 interacted with the mRNA of the five genes 
analyzed in the present study, although higher mRNA levels were found in the 3’biotinylated-
miR-101 pulldowns (Figure 4C). 
Discussion 
High-throughput sequencing has revealed the existence of miRNA sequence variants for 
virtually all miRNAs in many species and tissues and in both physiological and pathological 
conditions [16,43]. This scenario suggests a functional role for isomiRs that may introduce a 
new layer of complexity in gene expression regulation. Here, we characterized the 
functionality of a highly abundant type of miR-101 variant that differs in the seed region. 
miR-101 has mainly been studied for its tumor suppressive functions, by directly targeting 
EZH2, Cox-2, Mcl-1 and Fos [31,39,41,44-46]. miR-101 has also been shown to modulate 
the expression of target genes involved in inflammatory processes [42], autophagy [47] and 
angiogenesis [30]. In addition, our analysis showing the regulated expression of miR-101 in 
brain development and ageing and in a neurodegenerative process suggests important roles 
for this miRNA in nervous system physiology and pathology. Reinforcing this idea, genes 
that are relevant in brain function including APP [48] and ATX1 [49] are proven targets of 
miR-101. 
For the majority of miRNAs, the most abundant isomiRs include 3’-trimming variants and 
nucleotide additions in the 3’-end [50], suggesting that modifications in the 3’ end are more 
permissive. In contrast, the diversity and abundance of isomiRs affecting the 5’-end of 
mature miRNAs (5’-trimming variants) is considerably reduced, which may be indicative of 
an increased impact of these variants in biological processes. In fact, miRNA 5’-trimming 
variants show a modified seed region (nucleotides 2–8 of the mature sequence) which is one 
of the major determinants defining target genes [50,51]. Thus, for a given miRNA, isomiRs 
expressed in high amounts which differ in the seed region are expected to have some impact 
on gene expression regulation. Our results show that among all the sequences mapping onto 
miR-101, 5’-trimming variants affecting a single nucleotide position are highly abundant in 
human samples and show variable expression depending on the sample. This suggests that the 
biogenesis and/or stability of miR-101 isomiRs are dependent on the cell context. 5’-
trimming isomiRs may be generated by variations of the Dicer-cutting site on the precursor 
miRNA. In support of this idea, both types of miR-101 variants are strongly and similarly 
decreased (data not shown) when analyzing publicly available sRNA sequencing datasets in 
MCF-7 cells knocked down for Dicer [52]. Recent results indicate that Dicer activity can be 
modulated by a number of proteins, interacting either with Dicer or with miRNA precursors 
[53]. Thus, whether differential modulation of Dicer activity in diverse cell types and/or 
physiological conditions is underlying the relative abundance of 5’-trimming miR-101 
isomiRs is an open question that deserves specific research. 
Another possible mechanism accounting for the differential abundance of all variants 
mapping onto miR-101 may be related to the stability of the mature forms. It has been shown 
that the post-transcriptional addition of non-genome-encoded nucleotides to the 3’ end of 
mature miRNA increases miRNA stability or abundance [24,54]. However, the proportion of 
species with 3’-nucleotide additions mapping as miR-101 or 5’-isomiR-101 did not correlate 
with the differential miR-101/5’-isomiRs-101 relative abundance detected in the samples 
examined (data not shown). This suggests that nucleotide additions may not be a major 
explanation for the differential relative abundance. 
Several findings indicate that miR-101 5’-trimming variants are functional silencing sRNA: i) 
both 5’-isomiR-101 mimic and endogenous 5’-isomiR-101 were loaded into Ago2 
immunocomplexes, ii) biotin-streptavidin pull-down showed that 5’-isomiR-101 binds to 
both Ago2 and Rck/p54 RISC components iii) biotinylated 5’-isomiR-101 pull-down assays 
purified known miR-101 target mRNAs and iv) 5’-isomiR-101 mimic inhibited the 
expression of known miR-101 targets. 
In trying to identify possible candidates that are differentially modulated by miR-101 and 5’-
isomiR-101, high-throughput array-based approach failed to show significant regulation of 
mRNAs by either variant. It may be that miR-101 modulates gene expression mainly at the 
translational level, producing mild effects on RNA levels that are difficult to verify in a 
microarray approach. In spite of this, the arrays identified a small number of genes that were 
regulated by only one type of variant. In addition, the non-overlapping anti-correlation 
between the expression profiles of miR-101 variants and a number of age-related genes in the 
human brain agrees with specific miR-101- and 5’-isomiR-101 gene targeting. Although 
selective functions of the seed variants may add complexity to miR-101 regulatory effect, it 
has been proposed that isomiRs function cooperatively to target common biological pathways 
[55]. In agreement with this suggestion, the high number of commonly predicted targets 
indicates that similar biological pathways are regulated by isomiR-101 and 5’-isomiR-101. 
A number of results suggest that 5’-isomiR-101 is less efficient than miR-101 in gene 
silencing: i) determinations of 5’-isomiR-101 and miR-101 with highly specific RT-PCR 
assays in IPs of endogenous Ago2 indicate that miR-101 is more efficiently loaded into the 
RISC, although the analysis of SH-SY5Y small RNA sequencing data suggests that 5’-
isomiRs-101 are more abundant than the reference miR-101; ii) increased amounts of miR-
101 were also detected in Ago2 IPs of SH-SY5Y cells transfected with equivalent quantities 
of miR-101 or 5’-isomiR-101 mimics; iii) biotinylated miR-101 bound increased amounts of 
both Ago2 and Rck/p54 RISC members compared with biotinylated 5’-isomiR-101 and iv) 
5’-isomiR-101 showed a decreased ability to inhibit several miR-101 targets. Overall, these 
data indicate that the silencing activity of miR-101 variants is related to their efficient loading 
into the RISC and further suggest that the amount of the different miR-101 variants expressed 
within a cell does not strictly correlate with the quantities detected in the Ago2 complexes. 
Since Ago2 is the only Ago with mRNA slicing activity, decreased loading of 5’-isomiR-101 
onto Ago2 may explain the less efficient gene silencing of at least some target genes showing 
RNA destabilization. However, the reduced loading of 5’-isomiR-101 in Ago1 and Ago3 
detected in monocytic human cells suggests that less efficient binding to other Agos may 
contribute to the decreased silencing at the protein level. It has been shown that the 5’-
terminal residue in a miRNA influences its loading into the RISC, with terminal 5’-U 
enhancing the Ago2 complex [56]. Thus, the 5’ terminal G in the isomiR may provide a less 
efficient incorporation into the RISC. 
Our analysis suggests that the relative amount of the two main miR-101 seeds was not 
equivalent in the different Agos in monocytic human cells. It has recently been shown that a 
subset of miRNAs give rise to distinct isomiRs which associate mainly with distinct Ago 
proteins, both in plants [57] and in human samples [58,59], supporting an isomiR-dependent 
differential output in gene silencing. 
Conclusions 
In summary, our data show that 5’-isomiR-101 is a functional silencing small RNA. We 
propose that in addition to specific gene targeting, 5’-isomiR-101 variants present a subtle 
effect through regulatory mechanisms involving decreased silencing efficiency. Changes in 
the relative expression of seeds ratios may provide scenarios for isomiR-selective qualitative 
and quantitative gene expression regulation. This may add complexity to the fine-tuned 
nature of miRNA regulation of gene expression. 
The mechanisms by which miR-101 variants are generated and a full characterization of the 
repertoire of targets modulated by miR-101 and 5’-isomiR-101 may shed light on the 
respective biological function. Extensive study of these aspects will broaden our 
understanding of the overall biological impact of isomiRs in different tissues and 
physiological states. 
Methods 
Antibodies and reagents 
Anti-Ago2 was from Millipore, anti-Rck/p54 was from MBL, anti-Mcl-1 was from Cell 
Signaling, anti-COX-2 was from Cayman, anti-EZH2 was obtained from Dr. Kristian Helllin 
(BRIC-University of Copenhagen), anti-MKP-1 was from Santa Cruz, anti-APP was from 
Abcam and anti-tubulin and anti-FLAG (M2) were from Sigma. miRIDIAN™ hsa-miRNA-
101 mimics and siGLO Green (transfection indicator) were from Dharmacon: hsa-miRNA-
101 (mature sequence: UACAGUACUGUGAUAACUGAA), hsa-5’-isomiR-101 (mature 
sequence: GUACAGUACUGUGAUAACUGA), 3’biotinilated hsa-miRNA-101 (mature 
sequence: UACAGUACUGUGAUAACUGAA-Bio) and 3’biotinilated hsa-5’-isomiR-101 
(mature sequence: GUACAGUACUGUGAUAACUGA-Bio). 
Human samples 
Brain samples of individuals without clinical neurological disease and no major 
histopathological lesions were obtained from the Institute of Neuropathology and the 
University of Barcelona Brain Bank, after the informed consent of the patients or their 
relatives and the approval of the local ethics committee had been given. Blood samples of 
healthy individuals without clinical neurological disease were obtained from the Hospital 
Clinic of Barcelona after written informed consent of the participants and approval of the 
local Ethics Committee had been given. 
RNA sequencing and miR-101 variability analysis 
We used publicly available small RNA sequencing datasets from the GEO repository 
(GSE31069, GSM522374, GSE16579, GSE18069). In addition we sequenced small RNA in 
human blood samples (4 individuals), human brains (amygdala area of 4 individuals without 
major neurodegenerative histopathological signs) and SH-SY5Y neuroblastoma cells before 
and after differentiation to a postmitotic phenotype as previously described [60]. In these 
samples, total RNA was isolated using PAXgene blood RNA Kit (Qiagen) or the miRNAeasy 
kit (Qiagen). From each sample, 1µg of total RNA was used to prepare libraries according to 
the “TruSeq Small RNA Sample Preparation Guide” (Part# 15004197 Rev. A). Libraries 
were subsequently sequenced on one Illumina Genome Analyzer II run using 36 single-read 
cycles. For processing of the sequencing data (recognition and removal of the adapter) and 
characterization of miRNA variants we used a stand-alone version of the Seqbuster tool 
(http://estivill_lab.crg.es/seqbuster [50]). The parameters were set up to detect isomiRs by: a) 
trimming at the 3’/5’-end (up to 3 nucleotides shifted from the reference dicing site), b) 
addition at the 3-end (up to 3 nucleotides added) and c) nucleotide substitution (up to 1 
mismatch with respect to the reference miRNA sequence). 
miR-101/ age-related genes expression-correlation studies in the human brain 
To identify the genes differently expressed in the brain at different ages we applied the same 
method described by Somel et al. [26]. Briefly, the intensity of gene expression at 12 
different time-points along life was used to correlate to age. Expression was fitted to 8 non-
linear functions capable of detect linear, quadratic or more complex correlation between gene 
expression levels and age. All genes that fitted to one of those 8 models with p-value lower 
than 0.01 were considered age-related genes. 
We considered an age-related gene to be targeted by miR-101 or 5’-isomiR-101 sequences 
only if: i) there is a pair complementary between the miRNA seed and the gene according to 
TargetScan Custom prediction algorithm [37] and ii) there is a negative expression 
correlation between the miRNA sequence and the gene. Only those genes that have been 
detected in the gene expression profile of the brain samples, according to the public data from 
the original work, were used as input for TargetScan Custom algorithm. For each miR-101-
sequence-gene pair predicted by TargetScan Custom, a linear regression model was 
performed by the standard R function (’lm’). To consider a gene regulated by a miR-101 
variant, the p-value of the model should be less than 0,01 (F-test) and Pearson’s product 
moment correlation lower than −0.70. Normalized intensities of microarray data for gene 
expression, and logarithms of counts for miRNA sequences were used. The numbers of 
assigned miR-101 or 5’-isomiR-101 predicted targets were calculated according to the first 
requirement (seed match) or both of them (seed match and anti-correlation). The statistical 
differences between the numbers of commonly predicted miR-101 and 5’-isomiR-101 targets, 
considering or not the anti-correlation criterion was determined with the prop.test function in 
R. 
Cell cultures 
SH-SY5Y and SH-SY5Y cells stably expressing Ago2-FLAG (SH-SY5Y-Ago2-FLAG) [61] 
were cultured at 37°C in a 95:5 air/CO2 water saturated atmosphere in 1:1 mixture of DMEM 
and Ham’s F12 medium and 10% supplemental fetal bovine serum. For cell transfection, SH-
SY5Y cells were seeded at 0.2 x 106 and 50 ng of hsa-miRNA mimic or SiGLO Green 
(Control) were transfected with Lipofectamine Plus according to the manufacturer’s 
instructions. For western-blotting, 48 h post-transfection the medium was removed and the 
cells were washed twice with cold phosphate-buffered saline (PBS) and lysed with Lysis 
Buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1.5 mM EGTA, 1 mM 
EDTA, 1% Triton X-100, 1 mM DTT, and Protease and Phosphatase Inhibitors). After 15 
min on ice, the lysate was removed from the dishes and centrifuged at 12,000 g for 20 min at 
4°C. Supernatants were quantified using Bradford method and kept until use. For RNA 
analysis cells were harvested and treated as described above. 
Affinity purification of miRNA complexes 
Biotin-tagged miRNA complexes were purified as described before [62]. Briefly, transfected 
SH-SY5Y cells were harvested 48 h after transfection, washed in PBS and scraped in 1 ml of 
lysis buffer (20 mM Tris; pH 7.5, 200 mM NaCl, 2.5 mM MgCl2, 0.05% Igepal, 60 U 
Superase-In/ml (Ambion), 1 mM DTT and Pefabloc (Roche). Lysate was vortexed twice for 
20 seconds and cleared by spinning at 12,000g at 4 °C for 20 min in a microcentrifuge. Fifty 
µl of the sample were saved for input analysis and placed on dry ice. The remaining lysate 
was incubated for 1 h at 4 °C rotating with 25 µl pre-washed streptavidin-sepharose beads. In 
order to prevent non-specific binding of RNA and protein complexes, the beads were coated 
with RNase-free BSA and yeast tRNA (both from Ambion). Beads were washed three times 
with 500 µl ice-cold lysis buffer. In order to isolate the RNA, TRIzol was added to both input 
and affinity-washed beads. 40 µl of chloroform was added and after shaking samples were 
spin at 12,000 g at 4 °C for 15 min in a microcentrifuge. Supernatant was transferred to a 
fresh tube and RNA was precipitated adding 1 µl of GlycoBlue co-precipitant (Ambion), 6 µl 
of 5 M NaCl and 360 µl of ice-cold 95% ethanol overnight at −20 °C. Samples were pelleted 
at 12,000g for 15 min at 4°C, washed in 70% ethanol in RNase-free water and air-dried. RNA 
was dissolved in 120 µl of RNase-free water (Ambion). In order to isolate the proteins bound 
to the biotynilated miRNAs, washed beads were resuspended in SDS-buffer and boiled at 
100°C. 
The microRNA fraction from human frontal cortex lysate was purified using the microRNA 
isolation kit from Wako based on Ago2 immunoprepipitation complexes, following 
manufacturer’s instructions. 
Western-blot 
The protein content of either immunoprecipitations or cellular extracts were run on 8%-12% 
SDS-PAGE gels, transferred on to PVDF membranes, and incubated with the corresponding 
antibodies at the following concentrations: Ago-2 1:2000; Rck/p54: 1:1000; Mcl-1: 1:1000; 
COX-2: 1:500; EZH2: 1:1000; MKP-1: 1:250; APP: 1:1000; Tubulin: 1:10.000. The 
membranes were developed with the enhanced chemiluminescence method (ECL) following 
the manufacturer’s instructions. 
mRNA expression arrays 
SH-SY5Y cells were transfected with miR-101 or 5’-isomiR-101 as previously described in 
three independent experiments, and total RNA was isolated 48 h later. RNA concentration 
was measured with a Nanodrop™, and RNA quality was assessed by Bioanalyzer™ with 
RIN (RNA integrity number) ranging between 9 and 10. For each sample, 200 ng of total 
RNA was reverse transcribed, amplified by in vitro transcription and labeled with biotin-UTP 
using the Illumina Total Prep RNA amplification kit (IL1791, Applied Biosystem/Ambion, 
Austin, TX, USA) following the manufacturer’s instructions. 750 ng of biotinylated cRNA 
was hybridized in a BeadChip Hyb Chamber with rocking for 16 h at 58°C. Bead arrays were 
washed and blocked in a rocking incubator. Finally, bead arrays were dried by centrifugation 
followed by scanning in the Illumina Beadstation. The raw data were summarized per probe 
using BeadStudio software Gene Expression. The SAM (significance analysis of 
microarrays) two-class unpaired comparison test was applied to detect significant differences 
in gene expression between treated and control conditions, initially setting the statistical 
significance at a false discovery rate of 5%, with an arbitrary absolute fold chance cutoff set 
at 1.2. 
RT-qPCR 
miRNA-RT-qPCR 
Quantitative real time PCR was performed using the miRCURY LNA™ microRNA PCR 
System (Exiqon) on total RNA extracted from SH-SY5Y with mirVana’s isolation kit 
(Ambion) following the manufacturer’s instructions. PCR amplification and detection were 
performed with the ROCHE LightCycler 480 detector, using 2x SYBR GREEN Master Mix. 
The reaction profile was: Polymerase Activation/Denaturation cycle (95°C for 10 min) 
followed by 40 amplification cycles (95°C-10”, 60°C-20”). Each sample was amplified in 
triplicate. miRNA levels were calculated using the LightCycler 480 software. Both problem 
and calibrator samples were normalized by the relative expression of reference small non-
coding RNAs (SNORD44 and SNORD48). 
mRNA RT-qPCR 
Total RNA was extracted from SH-SY5Y cells with mirVana isolation kit (Ambion). Purified 
RNAs were treated with RNase-free DNAse (DNA-free, Ambion) and reverse-transcribed, 
with Superscript II (Invitrogen) to generate the corresponding cDNAs that served as PCR 
templates for mRNA quantification. The primers used for RT-qPCR were (5’->3’): COX-2; 
F-CCTGTGCCTGATGATTGC, R-CTGATGCGTGAAGTGCTG, MCL-1; F-
AAAGAGGCTGGGATGGGTTT, R-CAAAAGCCAGCAGCACATTC, APP; F-
TCAGGTTGACGCCGCTGT, R-TTCGTAGCCGTTCTGCTGC, EZH2; F-
AGTGTGACCCTGACCTCTGT, R-AGATGGTGCCAGCAATAGAT, DUSP-1 F-
CAGCTGCTGCAGTTTGAGTC, R- AGAGGTCGTAATGGGGCTCT. PCR amplification 
and detection were performed with the ROCHE LightCycler 480 detector, using 2X SYBR 
GREEN Master Mix as reagent following the manufacturer’s instructions. The reaction 
profile was: denaturation/activation cycle (95º for 10 min) followed by 40 cycles of 
denaturation-annealing-extension (95º-10’, 60º-40”, 72º-10”) and a final melting cycle (95º-
5’, 72º-10”, 98º-continuous). Each sample was amplified in triplicate. mRNA levels were 
calculated using the LightCycler 480 software. Samples were normalized by the relative 
expression of housekeeping gene (Tubulin). 
Statistical methods 
Statistical analysis was performed with G-STAT software (http://www.gstat.org). The Mann–
Whitney non-parametric test was used for the statistical analysis (two-tailed) of the RT-qPCR 
and western blot assays in transfection experiments; P≤ 0.05 was considered statistically 
significant. 
In Figures 3A and 4C, results are expressed as the mean of the Fold Change ratios 
(microRNA - Biotin-mRNA / control siGLO - Biotin) ± SEM. In Figure Error! Reference 
source not found.B and 3D, results are expressed as the mean of the Fold Change ratios 
(FLAG-Ago2 Antibodies / control Antibodies) ± SEM. In Figure 3C, a miRNA-101 
transfected sample was used to normalize data and assigned a value of 1 (Arbitrary Units). In 
Figure Error! Reference source not found.A and 4B, a control sample was used to 
normalize Fold Change values in each set of experiments and SEM was calculated. This 
control sample was assigned a value of 1. 
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Additional file 1: Table S1 miR-101 variants in the human striatum, amigdala and frontal 
gyrus (Somel et al., 2010) brain areas. The different sequences annotating to miR-101, the 
respective frequencies and lenghts are shown. For the 5’ and 3’ trimming variants, the 
number of nucleotides upstream (up) or downstream (down) of the reference miRBase miR-
101, are shown. The nucleotides involved in the 5’- and 3’ variant are next indicated. In 3’-
addition variants, the number and type of nucleotides added to the 3’-end are shown. In the 
nucleotide substitution variants, the affected position is first indicated; the pair of nucleotides 
that follow next indicates the substituted and the original nucleotides, respectively. Only 
variants with more than 10 counts were considered. The sequences mapping onto miR-101 
locus that represent the reference miR-101 sequence (in blue) and the 5’-isomiR-101 (in red) 
contained in a grey box. 
Additional_file_2 as JPEG 
Additional file 2: Figure S1 miR-101 and 5’isomiR-101 frequency distribution in different 
Agos. A. Normalized expression levels of all sequences mapping onto miR-101 (blue bars), 
5’-isomiR-101 seed (red bars) and reference miR-101 seed (green bars) in Ago1-Ago3 IP and 
in total cell extracts (Total). B. Table showing several determinations of miR-101 sequences. 
Freq. indicates the total count number; Number of variants indicates the sequence diversity 
for mIR-101; Norm. Freq., indicates the normalized frequency calculated as freq. miR-
101/freq. mIRNAs *10E6. 
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Additional file 3: Table S2 Genes differently expressed after transfection with isomiR-101 
mimic or a scrambeled (scr) sequence. The threshold for significant regulation is considered 
as a variation in the expression fold change above 1,2 or below -1,2 and a false discovery rate 
below 5 % (q<5), whch is indicated in bold. The MiRWalk database on predicted and 
validated microRNA targets (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) was used to highlight additional information: i) 
The prediction of the deregulated genes as putative targets for miR-101 by different 
algorithms (-, indicates no prediction and na information not available) and ii) the presense of 
putative miR-101 target seed sites in regions other than the 3’-UTR (-, indicates no sites and 
na information not available). In the last column, the custom Targetscan 5.2 prediction 
algorithm was used to highlight putative 5’-isomiR-101 targets. 
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Additional file 4: Table S3 Genes differently expressed after transfection with 5’-isomiR 
101 mimic or a scrambeled (scr) sequence. The threshold for significant regulation is 
considered as a variation in the expression fold change above 1,2 or below -1,2 and a false 
discovery rate below 5 % (q<5), whch is indicated in bold. The MiRWalk database on 
predicted and validated microRNA targets (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) was used to highlight additional information: i) 
The prediction of the deregulated genes as putative targets for miR-101 by different 
algorithms (-, indicates no prediction and na information not available) and ii) the presense of 
putative miR-101 target seed sites in regions other than the 3’-UTR (-, indicates no sites and 
na information not available). In the last column, the custom Targetscan 5.2 prediction 
algorithm was used to highlight putative 5’-isomiR-101 targets. 
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Additional file 5: Figure S2 Anti-correlation of age-related genes and miR-101 and 5’-
isomiR-101 expression profiles. A. Distribution of the numbers and percentages of age-
related genes (blue) targeted by miR-101 (red) and 5’-IsomiR-101 (green) seeds, according to 
TargetScan algorithm. B. Expression profile of the more abundant miR-101 and 5’-isomiR-
101 sequences, and two example age-related genes. NYAP2 expression anti-correlated with 
that of 5’-isomiR-101, and SCN3B expression anti-correlated with that of miR-101 
(considering an anti-correlation threshold < −0,7). 
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